Current Report Filing (8-k)
November 21 2016 - 10:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
_________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
November 15, 2016
Date of Report (Date of earliest
event reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
WYOMING
|
36-4787690
|
(State or other jurisdiction of
|
(I.R.S. Employer
|
incorporation or organization)
|
Identification No.)
|
(Exact name of registrant as specified in charter)
Suite 400, 41 University Drive
Newtown,
Pennsylvania, 18940
(Address of principal executive offices) (Zip
Code)
Registrants telephone number, including area code: (215)
809-2018
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
1
Item 1.01 Entry into a Material Definitive Agreement
On November 21, 2016, Helius Medical Technologies, Inc. (the
"Company" or Helius) announced that NeuroHabilitation Corporation (NHC), a
division of Helius, successfully executed an amendment to the sole source cost
sharing contract entered into with the U.S. Army Medical Research and Materiel
Command (USAMRMC). The contract extends the agreement with USAMRMC to December 31, 2017 and is
under the larger Cooperative Research and Development Agreement (CRADA)
framework with the United States Army. The modification allows Helius to
include additional study sites for the clinical trial investigating the safety
and effectiveness of the Portable Neuromodulation Stimulator (PoNS) for the
treatment of chronic balance deficits in subjects with mild to moderate
traumatic brain injury.
Item 8.01 Other Events.
On November 21, 2016, the Company issued a press release
announcing the information discussed in this Item 1.01. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
2
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
HELIUS MEDICAL TECHNOLOGIES,
INC.
|
|
|
|
Dated: November 21, 2016
|
By:
|
/s/
Joyce LaViscount
|
|
|
Joyce LaViscount, Chief Financial Officer
|
3
EXHIBIT INDEX
4
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2023 to Mar 2024